Patents Assigned to Sumitomo Dainippon Pharma Co., Ltd.
  • Publication number: 20220144927
    Abstract: The present invention aims to provide a humanized antibody or an antigen-binding fragment thereof having stable physical property, superior in tumor accumulation, and capable of binding to mucin subtype 5AC. The above-mentioned problem is solved by the present invention that provides a humanized antibody or an antigen-binding fragment thereof having a heavy chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 1-4 or a mutated amino acid sequence thereof, and a light chain variable region consisting of the amino acid sequence shown in SEQ ID NO: 5-8 or a mutated amino acid sequence thereof, and capable of binding to mucin subtype 5AC.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 12, 2022
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Mitsuhiro MATONO, Jun SAKAI, Toru NAGAI, Naoki TANUMA, Richard BUICK
  • Publication number: 20220144889
    Abstract: A compound represented by formula (1): wherein b represents an integer of 1 to 5; X represents —NH— or —CO—; Z represents a group represented, for example, by formula (Z-1); R1 represents a hydrogen atom or (AB)m; AB represents a particular amino acid residue, and when there is a plurality of ABs, each AB may be the same as or different from each other and ABs are bonded to each other via an amide bond; m represents an integer of 1 to 9; R2 represents a hydroxy group or (AC)g; AC represents a particular amino acid residue, and when there is a plurality of ACs, each AC may be the same as or different from each other and ACs are bonded to each other via an amide bond; and g represents an integer of 1 to 9, or a salt thereof.
    Type: Application
    Filed: February 12, 2020
    Publication date: May 12, 2022
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventor: Atsushi Suwa
  • Publication number: 20220143020
    Abstract: The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1) [wherein X1 represents CR1 or N, X2 represents CR2 or N, X3 represents CR3 or N, Y represents an optionally substituted C6-10 aryl or optionally substituted 6 to 10-membered heteroaryl, Z represents an optionally substituted C6-10 aryl, RA represents a hydrogen atom, halogen, cyano, optionally substituted C1-6 alkyl sulfonyl, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy, and R1, R2, and R3 independently represent a hydrogen atom, halogen, optionally substituted C1-6 alkyl, or optionally substituted C1-6 alkoxy] or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 28, 2020
    Publication date: May 12, 2022
    Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventor: Tomoyuki FURUTA
  • Patent number: 11325921
    Abstract: The present invention relates to the compound of formula (I) wherein p is 1 or 2, R1 is —CF3 or the like, R2a, R2b, R3a, and R3b are hydrogen atom or the like, X is —C(?O)—or the like, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: May 10, 2022
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji Kamioka, Naoaki Shimada, Wataru Hirose, Hitoshi Ban, Akihiko Yokoyama
  • Publication number: 20220125941
    Abstract: A compound represented by formula (1): wherein R1 represents a hydrogen atom or a sulfonyl group; and Z represents a group represented by formula (Z-1), or a salt thereof.
    Type: Application
    Filed: February 12, 2020
    Publication date: April 28, 2022
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Atsushi Suwa
  • Patent number: 11312688
    Abstract: The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT2C inverse agonistic action comprising Compound (1): or a pharmaceutically acceptable salt thereof wherein R1, R2, R3 and R4 are independently hydrogen or C1-6 alkyl etc.; R5 is C4-7 alkyl or —(CR8R9)r-E; R6, R7, R8 and R9 are independently hydrogen, fluorine or C1-6 alkyl; A is C6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C3-8 cycloalkyl or C6-10 aryl etc.; L is oxygen, sulfur or —NR10—; n is 1, 2 or 3; R10 is hydrogen or C1-6 alkyl etc.; and X is hydrogen or halogen etc.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: April 26, 2022
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Izumi Sasaki, Tomohiro Toyoda, Hidefumi Yoshinaga, Itaru Natsutani, Yoko Takahashi
  • Publication number: 20220120754
    Abstract: Disclosed is a method for selecting a potential subject with benefiting from a pharmaceutical composition for treating or preventing cancer, comprising: determining the presence or absence of a mutation in tumor protein p53 (TP53) gene and/or BCL6 co-repressor (BCOR) gene by using a sample collected from the subject; and providing an indication that the subject is a potential subject with benefiting from the pharmaceutical composition in the case of TP53 wild type and/or BCOR wild type.
    Type: Application
    Filed: February 27, 2020
    Publication date: April 21, 2022
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., International Institute of Cancer Immunology, Inc.
    Inventors: Erina YAMAKAWA, Masashi GOTO
  • Publication number: 20220119764
    Abstract: The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3): (1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state, (2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.
    Type: Application
    Filed: January 3, 2022
    Publication date: April 21, 2022
    Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Atsushi KUWAHARA, Suguru YAMASAKI, Yasushi HIRAMINE, Yoshiki SASAI (deceased), Masayo TAKAHASHI
  • Publication number: 20220112457
    Abstract: The present invention provides a method for producing neural cells or a neural tissue, including the following steps (1)-(3): (1) a first step of culturing pluripotent stem cells in the absence of feeder cells and in a medium containing 1) a TGF? family signal transduction pathway inhibiting substance and/or a Sonic hedgehog signal transduction pathway activating substance, and 2) a factor for maintaining undifferentiated state, (2) a second step of culturing the cells obtained in the first step in suspension to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence or absence of a differentiation-inducing factor to obtain an aggregate containing neural cells or a neural tissue.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., RIKEN, SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Atsushi KUWAHARA, Suguru YAMASAKI, Yasushi HIRAMINE, Yoshiki SASAI (deceased), Masayo TAKAHASHI
  • Patent number: 11299465
    Abstract: The present disclosure concerns at least one entity chosen from compounds of Formula (I) and pharmaceutically acceptable salts thereof: wherein the variable groups X, R1, R2, R3 m, n and p are as defined herein. The present disclosure also relates to methods for the preparation of at least one such entity, and intermediates useful in the preparation thereof, to pharmaceutical compositions containing at least one such entity, to the use of at least one such entity in the preparation of medicaments, and to the use of at least one such entity in the treatment of conditions such as, for example, allergic diseases, autoimmune diseases, viral diseases, and cancer.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: April 12, 2022
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Seiji Hori, Futoshi Hasegawa, Daisuke Urabe, Hirotaka Kurebayashi
  • Publication number: 20220081441
    Abstract: The present invention relates to a medicament for treating or preventing a disease related to orexin receptor, especially orexin type 2 receptor, comprising a new compound having a urea structure or a pharmaceutically acceptable salt thereof as an active ingredient. In more detail, the present invention relates to a medicament for treating or preventing narcolepsy, idiopathic hypersomnia, hypersomnia, sleep apnea syndrome, etc.
    Type: Application
    Filed: November 15, 2021
    Publication date: March 17, 2022
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Eiji IDEUE, Masafumi KOMIYA, Shoukou LEE, Shunichiro UESUGI, Yuta FUNAKOSHI
  • Patent number: 11273212
    Abstract: The present invention relates to a polypeptide consisting of an amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, (b) an amino acid sequence that differs from the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8 by substitution, deletion, addition, or insertion of 1 to 10, preferably 1-5, more preferably 1, 2 or 3 amino acids, and (c) an amino acid sequence that has at least 95%, preferably 97%, more preferably 99% sequence identity with the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, and a malaria vaccine comprising the polypeptide, for example.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: March 15, 2022
    Assignees: Sumitomo Dainippon Pharma Co., Ltd., National University Corporation Ehime University
    Inventors: Akihisa Fukushima, Takafumi Tsuboi, Eizo Takashima, Hikaru Nagaoka
  • Publication number: 20220073506
    Abstract: The present invention relates to a compound represented by formula (1): the compound having antagonist activity against serotonin 5-HT2A receptors and serotonin 5-HT7 receptors; or a pharmaceutically acceptable salt of the compound. (In the formula, Z is a nitrogen atom and the like; Y is carbonyl and the like; m and n are 1 and the like; R1a through R1d, R2a through R2d, and R4a through R4d are a hydrogen atom and the like; R3 is alkyl and the like; and Q is a specific bicyclic group.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 10, 2022
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Yuki FUJII, Masayuki SAKUMA, Yoshinori AIHARA, Jeremy BESNARD, Andrew Simon BELL
  • Patent number: 11266738
    Abstract: The present invention provides a compound of the formula (2): wherein X, R1, R2, R3, R4, R5, R6, R8, Y1, Y2, and L are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: March 8, 2022
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hidenori Kimura, Hitoshi Ban, Yoshiaki Isobe, Hitoshi Watanabe
  • Patent number: 11267797
    Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: March 8, 2022
    Assignees: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Yoshinobu Yoshimura, Masayasu Kasai, Yoshimichi Shoji, Shigemitsu Takeda
  • Publication number: 20220062421
    Abstract: The invention enables more efficient CTL induction by applying a transdermal preparation containing a WT1 protein-derived cancer antigen peptide and an ether-type additive, which is liquid at 20° C., to a WT1 protein-derived cancer antigen peptide. The ether-type additive is represented by the formula (1): R1—O—R2 (1), wherein R1 is a hydrocarbon group having 8-24 carbon atoms, and R2 is a group represented by the formula (2): or a group represented by the formula (3): —(CH2CH2O)mH (3), wherein m is an integer of 1-18.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 3, 2022
    Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Masayasu TANAKA, Kazumitsu YAMAMOTO, Hiroo MAEDA, Koichi SAITO, Natsuko SUGINOBE
  • Patent number: 11253476
    Abstract: The present invention provides a liposome useful as a vaccine adjuvant. More specifically, the present invention provides a liposome which comprises a lipid bilayer comprising dimyristoylphosphatidylcholine and egg phosphatidylglycerol and a conjugated compound in which a low-molecular weight compound enhancing the physiological activity of TLR7 is bound to squalene via a linker, said conjugated compound being encapsulated in the lipid bilayer.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: February 22, 2022
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventor: Akihisa Fukushima
  • Patent number: 11242332
    Abstract: The present invention relates to a process to prepare a benzimidazole derivative useful as a medicament, an intermediate for preparing the medicament, and a process to prepare the intermediate.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: February 8, 2022
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Shingo Mizushima, Shoukou Lee, Yoko Takahashi
  • Publication number: 20220008528
    Abstract: The present disclosure provides a composition for preventing or treating a benign tumor. Provided is a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a specific embodiment, the present disclosure provides a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a preferred embodiment, the composition for preventing or treating a benign tumor (e.g. familial adenomatous polyposis) according to the present disclosure comprises a killer type WT1 peptide and/or a helper type WT1 peptide. In a further preferred embodiment, the WT1 peptide is WT1126 killer peptide and/or WT135 helper peptide.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 13, 2022
    Applicants: International Institute of Cancer Immunology, Inc., Sumitomo Dainippon Pharma Co., Ltd.
    Inventor: Haruo SUGIYAMA
  • Publication number: 20220000834
    Abstract: The present invention addresses the problem of providing a formulation for applying a semaphorin inhibitor without surgery to remove the dura mater. A sheet formulation comprising a semaphorin inhibitor for treating spinal cord injury or brain injury by epidural administration is provided.
    Type: Application
    Filed: December 11, 2019
    Publication date: January 6, 2022
    Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Kiyokazu IWATA, Takashi NAKAGAWA, Shoji OGAWA, Mitsuhiro INOUE